Literature DB >> 27091529

Prevalence, Severity, and Prognostic Value of Sleep Apnea Syndromes in Cardiac Amyloidosis.

Diane Bodez1,2,3,4, Aziz Guellich1,2,3,4, Mounira Kharoubi1,2,3,4,5, Ala Covali-Noroc6, Claire-Marie Tissot1,2,3,4, Soulef Guendouz1,2,3,4, Luc Hittinger1,2,4, Jean-Luc Dubois-Randé1,2,4, Jean-Pascal Lefaucheur3,6, Violaine Planté-Bordeneuve2,3,7, Serge Adnot4,6, Laurent Boyer4,6, Thibaud Damy1,2,3,4,5.   

Abstract

STUDY
OBJECTIVES: To assess prevalence, severity, and prognostic value of sleep-disordered breathing (SDB), in the three main cardiac amyloidosis (CA) types, i.e., light-chain (AL), transthyretin-related familial (m-TTR), or senile (WT-TTR).
METHODS: Patients consecutively referred for CA diagnosis work-up underwent cardiac assessment and nocturnal polygraphy. SDB was defined as apnea-hypopnea index (AHI) ≥ 5/h. Multivariate analysis was used to identify predictors of a major adverse cardiac event (MACE) defined as death, heart transplantation and acute heart failure.
RESULTS: Seventy CA patients were included (31 AL, 22 m-TTR, 17 WT-TTR). The mean ± standard deviation age and left ventricular ejection fraction were 71 ± 12 years and 49% ± 13% and median (interquartile range) N terminal pro brain natriuretic peptide (NT-proBNP) was 3,932 (1,607; 7,028) pg/mL. The prevalence of SDB was 90% without difference between amyloidosis types. SDB was central in 27% and obstructive in 73%. AL had less frequent severe SDB compared to m-TTR and WT-TTR (P = 0.015) but longer time with peripheral capillary oxygen saturation (SpO2) < 90% (P = 0.037). After a median follow-up of 7.5 (2.8; 14.9) months, 49% patients experienced MACE. Time with nocturnal SpO2 < 90% was the only independent predictor of MACE. The best-identified threshold was 30 min. Values > 30 min were associated with bad prognosis (Log-rank χ(2): 8.01, P value = 0.005). Using binomial logistic regression, determinants of time with nocturnal SpO2 < 90% were New York Heart Association class (P = 0.011), and log-NT-proBNP (P = 0.04) but not AHI.
CONCLUSIONS: In CA population, prevalence of SDB is high (90%) and dominated by the obstructive pattern. Bad prognosis in this population was driven by nocturnal desaturation, reflecting heart failure severity and respiratory involvement.
© 2016 Associated Professional Sleep Societies, LLC.

Entities:  

Keywords:  cardiac amyloidosis; heart failure; prognosis; sleep-disordered breathing

Mesh:

Year:  2016        PMID: 27091529      PMCID: PMC4909615          DOI: 10.5665/sleep.5958

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  43 in total

Review 1.  Recommendations for the evaluation of left ventricular diastolic function by echocardiography.

Authors:  Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelista
Journal:  J Am Soc Echocardiogr       Date:  2009-02       Impact factor: 5.251

Review 2.  Systemic amyloidoses: what an internist should know.

Authors:  Giovanni Palladini; Giampaolo Merlini
Journal:  Eur J Intern Med       Date:  2013-11-18       Impact factor: 4.487

3.  Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure.

Authors:  P A Lanfranchi; A Braghiroli; E Bosimini; G Mazzuero; R Colombo; C F Donner; P Giannuzzi
Journal:  Circulation       Date:  1999-03-23       Impact factor: 29.690

4.  Sleep and exertional periodic breathing in chronic heart failure: prognostic importance and interdependence.

Authors:  Ugo Corrà; Massimo Pistono; Alessandro Mezzani; Alberto Braghiroli; Andrea Giordano; Paola Lanfranchi; Enzo Bosimini; Marco Gnemmi; Pantaleo Giannuzzi
Journal:  Circulation       Date:  2005-12-27       Impact factor: 29.690

Review 5.  Obesity and obstructive sleep apnoea: mechanisms for increased collapsibility of the passive pharyngeal airway.

Authors:  Shiroh Isono
Journal:  Respirology       Date:  2012-01       Impact factor: 6.424

6.  High prevalence of abnormal nocturnal oximetry in patients with hypertrophic cardiomyopathy.

Authors:  Mackram F Eleid; Tomas Konecny; Marek Orban; Partho P Sengupta; Virend K Somers; James M Parish; Farouk Mookadam; Peter A Brady; Barbara L Sullivan; Bijoy K Khandheria; Steve R Ommen; A Jamil Tajik
Journal:  J Am Coll Cardiol       Date:  2009-11-03       Impact factor: 24.094

7.  Hypoxia, not the frequency of sleep apnea, induces acute hemodynamic stress in patients with chronic heart failure.

Authors:  Joshua D Gottlieb; Alan R Schwartz; Joanne Marshall; Pamela Ouyang; Linda Kern; Veena Shetty; Maria Trois; Naresh M Punjabi; Cynthia Brown; Samer S Najjar; Stephen S Gottlieb
Journal:  J Am Coll Cardiol       Date:  2009-10-27       Impact factor: 24.094

8.  Central sleep apnea, right ventricular dysfunction, and low diastolic blood pressure are predictors of mortality in systolic heart failure.

Authors:  Shahrokh Javaheri; Rakesh Shukla; Haoyue Zeigler; Laura Wexler
Journal:  J Am Coll Cardiol       Date:  2007-05-04       Impact factor: 24.094

9.  Apnea-hypopnea and desaturations in heart failure with reduced ejection fraction: Are we aiming at the right target?

Authors:  Barnabas Gellen; Florence Canouï-Poitrine; Laurent Boyer; Xavier Drouot; Aurélie Le Thuaut; Diane Bodez; Ala Covali-Noroc; Marie Pia D'ortho; Soulef Guendouz; Stéphane Rappeneau; Mounira Kharoubi; Jean-Luc Dubois-Rande; Luc Hittinger; Serge Adnot; Sylvie Bastuji-Garin; Thibaud Damy
Journal:  Int J Cardiol       Date:  2015-11-18       Impact factor: 4.164

10.  Sympathetic neural mechanisms in obstructive sleep apnea.

Authors:  V K Somers; M E Dyken; M P Clary; F M Abboud
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

View more
  2 in total

Review 1.  Sleep Apnea: Types, Mechanisms, and Clinical Cardiovascular Consequences.

Authors:  Shahrokh Javaheri; Ferran Barbe; Francisco Campos-Rodriguez; Jerome A Dempsey; Rami Khayat; Sogol Javaheri; Atul Malhotra; Miguel A Martinez-Garcia; Reena Mehra; Allan I Pack; Vsevolod Y Polotsky; Susan Redline; Virend K Somers
Journal:  J Am Coll Cardiol       Date:  2017-02-21       Impact factor: 24.094

Review 2.  Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis.

Authors:  Alberto Aimo; Claudio Rapezzi; Federico Perfetto; Francesco Cappelli; Giovanni Palladini; Laura Obici; Giampaolo Merlini; Gianluca Di Bella; Matteo Serenelli; Mattia Zampieri; Paolo Milani; Roberto Licordari; Lucio Teresi; Nicolò Ribarich; Vincenzo Castiglione; Filippo Quattrone; Sabina De Rosis; Giuseppe Vergaro; Giorgia Panichella; Michele Emdin; Claudio Passino
Journal:  Eur J Clin Invest       Date:  2021-05-22       Impact factor: 4.686

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.